Bader Abbas, Begemann Madeline, Al-Obaidi Ammar, Habib Muhammad Hamza, Anwer Faiz, Raza Shahzad
University of Missouri Kansas City School of Medicine, 5000 Holmes St, Kansas City, MO 64110, USA.
Saint Luke's Hospital of Kansas City, 4401 Wornall Rd, Kansas City, MO 64111, USA.
Future Sci OA. 2023 Jun 1;9(7):FSO871. doi: 10.2144/fsoa-2022-0081. eCollection 2023 Aug.
Ocular complications of antineoplastic agents can have a profound effect on the quality of life of cancer patients. New oncologic treatments like monoclonal antibodies, immunotherapies, antibody-drug conjugates, checkpoint inhibitors and growth factor receptors have resulted in increased ocular complications. These ocular complications differs in respect to distinct mechanisms of actions and lead to significant challenges in the management of cancer patients. In this review, we reviewed literature, clinical studies and cases detailing ocular complications due to administration of antineoplastic agents and emphasized the need for communication between oncologists and ophthalmologists toward early detection and management of ocular complications.
抗肿瘤药物的眼部并发症会对癌症患者的生活质量产生深远影响。单克隆抗体、免疫疗法、抗体药物偶联物、检查点抑制剂和生长因子受体等新型肿瘤治疗方法导致眼部并发症增多。这些眼部并发症在作用机制上各不相同,给癌症患者的治疗带来了重大挑战。在本综述中,我们回顾了有关抗肿瘤药物给药引起的眼部并发症的文献、临床研究和病例,并强调肿瘤学家和眼科医生之间进行沟通以早期发现和处理眼部并发症的必要性。